deltatrials
Terminated NA NCT00087191

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

Distribution Of The Photosensitizer Motexafin Lutetium And Hypoxia In Patients With Malignancies

Sponsor: National Cancer Institute (NCI)

Conditions Advanced Adult Primary Liver Cancer Carcinoma of the Appendix Fallopian Tube Cancer Gastrointestinal Stromal Tumor Localized Extrahepatic Bile Duct Cancer Localized Gallbladder Cancer Localized Gastrointestinal Carcinoid Tumor Localized Resectable Adult Primary Liver Cancer Localized Unresectable Adult Primary Liver Cancer Metastatic Gastrointestinal Carcinoid Tumor Ovarian Sarcoma Ovarian Stromal Cancer Primary Peritoneal Cavity Cancer Recurrent Adult Primary Liver Cancer Recurrent Adult Soft Tissue Sarcoma Recurrent Colon Cancer Recurrent Extrahepatic Bile Duct Cancer Recurrent Gallbladder Cancer Recurrent Gastric Cancer Recurrent Gastrointestinal Carcinoid Tumor Recurrent Non-small Cell Lung Cancer Recurrent Ovarian Epithelial Cancer Recurrent Ovarian Germ Cell Tumor Recurrent Pancreatic Cancer Recurrent Rectal Cancer Recurrent Small Intestine Cancer Recurrent Uterine Sarcoma Regional Gastrointestinal Carcinoid Tumor Small Intestine Adenocarcinoma Small Intestine Leiomyosarcoma Small Intestine Lymphoma Stage 0 Non-small Cell Lung Cancer Stage I Adult Soft Tissue Sarcoma Stage I Colon Cancer Stage I Gastric Cancer Stage I Non-small Cell Lung Cancer Stage I Ovarian Epithelial Cancer Stage I Ovarian Germ Cell Tumor Stage I Pancreatic Cancer Stage I Rectal Cancer Stage I Uterine Sarcoma Stage II Adult Soft Tissue Sarcoma Stage II Colon Cancer Stage II Gastric Cancer Stage II Non-small Cell Lung Cancer Stage II Ovarian Epithelial Cancer Stage II Ovarian Germ Cell Tumor Stage II Pancreatic Cancer Stage II Rectal Cancer Stage II Uterine Sarcoma Stage III Adult Soft Tissue Sarcoma Stage III Colon Cancer Stage III Gastric Cancer Stage III Ovarian Epithelial Cancer Stage III Ovarian Germ Cell Tumor Stage III Pancreatic Cancer Stage III Rectal Cancer Stage III Uterine Sarcoma Stage IIIA Non-small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer Stage IV Adult Soft Tissue Sarcoma Stage IV Colon Cancer Stage IV Gastric Cancer Stage IV Non-small Cell Lung Cancer Stage IV Ovarian Epithelial Cancer Stage IV Ovarian Germ Cell Tumor Stage IV Pancreatic Cancer Stage IV Rectal Cancer Stage IV Uterine Sarcoma Unresectable Extrahepatic Bile Duct Cancer Unresectable Gallbladder Cancer
Interventions EF5 motexafin lutetium pharmacological study
Updated 6 times since 2017 Last updated: Jan 15, 2013 Started: May 31, 2004 Primary completion: Jan 31, 2006

Listed as NCT00087191, this NA trial focuses on Advanced Adult Primary Liver Cancer and Carcinoma of the Appendix and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated NA

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated NA

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated NA

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated NA

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated NA

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated NA

    First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Philadelphia, United States